Diamel
Asset
- Stage
- Phase 3, no development reported
- Modality
- Supplement
- Target
- Not known
- 2
- Indications
- 36
- Trials
- 1
- Developer
No development reported since April 2012. Last activity: Trial NCT00820651 completed. clinicaltrials.gov
Indications
2Insulin resistance
Phase 3, Completed, NCT00820651, clinicaltrials.gov, Nov 14, 2026
Metabolic dysfunction-associated steatohepatitis
Phase 3, Completed, NCT00820651, clinicaltrials.gov, Nov 14, 2026
In the full profile
- Target and mechanism2
- Owner and partners1
- Trials36
- Evidence for its targets2
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.